Ascletis Pharma Inc.

Investors

Financials & Filing

2025

2024

2023

2022

2021

2020

2019

2018

Inside Information - Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide
2025-03-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
2025-03-05
Inside Information - Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30
2025-02-19
Next Day Disclosure Return
2025-02-13
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
2025-02-05
Poll Results of the Extraordinary General Meeting Held on February 3, 2025
2025-02-03
Next Day Disclosure Returns - Share Buyback
2025-01-24
Next Day Disclosure Returns - Share Buyback
2025-01-23
Voluntary Announcement - Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update
2025-01-21
Next Day Disclosure Returns - Share Buyback
2025-01-16

4

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1